The Peptide NewsroomPeptide research, industry and supply-chain headlines

Review Scores Peptide Vendor Cellugenix 9.5 Out of 10, But the Data Is Self-Reported

Topic card: fda supply

A vendor review published on Nerdbot scores research-peptide supplier Cellugenix 9.5 out of 10, crediting a public certificate-of-analysis library, documented 99%+ purity, and batch testing through a named independent lab.

Cellugenix sells lyophilized peptides labeled research-use-only, including BPC-157, TB-500, GHK-Cu, CJC-1295 and MOTS-c. A certificate of analysis is the lab paperwork describing what is actually in a given batch, and a batch-specific one is the only way a claim of 99% purity can be matched to the vial it supposedly describes.

The named lab is the real finding

The review states that every batch is verified through an independent laboratory, Testides, at 99%+ purity, with certificates tied to specific batch numbers. Naming the lab is a smaller-sounding detail than the headline score and a more useful one, because most of this market says "third-party tested" and stops there.

Purity is not the whole certificate

The piece also does something vendor reviews rarely bother with, pointing to peer-reviewed work on cell-culture contamination showing a peptide can read as highly pure and still carry biologically active endotoxin, a bacterial residue that standard purity testing does not capture. The 2026 benchmark it sets is HPLC purity, mass-spectrometry identity confirmation, endotoxin screening, and a named independent lab.

Where the verification stops

Every figure here originates with the company or its own documentation as of August 2026, and the review says as much: it reflects "what we could verify from its site and documentation." No samples were independently tested for the review, the reviewer concedes the brand is quieter about upstream manufacturing detail, and its own reputation subscore is the lowest on the card at 8, on the grounds that the independent review record is still thin.

Not approved for human use

Everything in the catalog is research-use-only material that is not FDA-approved for human use. The review notes that BPC-157 was reclassified by the FDA out of Category 2 in early 2026 but remains prohibited for athletes, quoting the U.S. Anti-Doping Agency that it "has not been extensively studied in humans," so "it is unknown if there is a safe dose."

Bottom line

The documentation story is the interesting part, and published batch certificates from a named lab are a genuinely higher bar than most of this sector clears. What a 9.5 cannot tell you is anything an independent assay would, because nobody ran one.

Source: RSS.app — Peptides bundle. Read the original.

Filed under: fda, supply, safety

Comments (0)

Discussion happens on Reddit.
Questions and corrections go to r/PeptideNewsroom.

Go to r/PeptideNewsroom

Corrections are the most useful thing you can post. Comments touching dosing, sourcing or links are held for a moderator first.

More from The Peptide Newsroom

HHS Won't Act Against Six Unapproved Peptides, But FDA Reviewers Advised Against Listing Them

HHS says it will not act against pharmacies compounding BPC-157, TB-500, KPV, MOTS-c, Semax, and Epitalon, despite FDA reviewers recommending against listing all six. The notice sets no end date, adds no test of the finished vial, and is open for public comment through November 13.

HHS Opens Compounding to BPC-157 and Five Peptides, But FDA Scientists Objected

HHS will allow state-licensed pharmacies to compound BPC-157, TB-500, epitalon, MOTS-c, KPV and semax under quality conditions, while stating the policy does not establish safety or effectiveness. FDA reviewers had found the BPC-157 studies too small and no human safety studies at all for four of the six.

FDA Sends Interim Peptide Compounding Policy to White House, But Experts Say Access Isn't Approval

The FDA has sent an interim peptide compounding policy to the White House, which could let pharmacies compound unapproved peptides including BPC-157 while permanent rules are written. Pharmacists and physicians quoted in the coverage stress that enforcement discretion is not approval and not evidence of safety.